Identification
- Summary
Potassium sulfate is an osmotic laxative used to cleanse the colon before a colonoscopy.
- Brand Names
- Suprep Bowel Prep Kit
- Generic Name
- Potassium sulfate
- DrugBank Accession Number
- DB14499
- Background
Not Available
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Potassium sulfate (DB14499)
- Weight
- Average: 174.259
Monoisotopic: 173.8791429 - Chemical Formula
- K2O4S
- Synonyms
- Dipotassium sulfate
- Potasio sulfato
- Potassium (as sulfate)
- Potassium sulfate
- Potassium sulphate
- Sulfato potasio
- Sulfuric acid, dipotassium salt
- External IDs
- E-515(I)
- Ins no.515(I)
- Ins-515(I)
Pharmacology
- Indication
Potassium is used to regulate hypokalemia as a primary condition or secondary to other medical conditions.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Therapies
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Potassium is the major cation (positive ion) inside animal cells, while sodium is the major cation outside animal cells. The concentration differences of these charged particles causes a difference in electric potential between the inside and outside of cells, known as the membrane potential. The balance between potassium and sodium is maintained by ion pumps in the cell membrane. The cell membrane potential created by potassium and sodium ions allows the cell generate an action potential—a "spike" of electrical discharge. The ability of cells to produce electrical discharge is critical for body functions such as neurotransmission, muscle contraction, and heart function. Potassium is also an essential mineral needed to regulate water balance, blood pressure and levels of acidity.
Target Actions Organism USodium/potassium-transporting ATPase subunit alpha-1 Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Mostly urine but also skin and feces.
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Abacavir may decrease the excretion rate of Potassium sulfate which could result in a higher serum level. Acebutolol Potassium sulfate may increase the hyperkalemic activities of Acebutolol. Aceclofenac Potassium sulfate may increase the hyperkalemic activities of Aceclofenac. Acemetacin Potassium sulfate may increase the hyperkalemic activities of Acemetacin. Acetaminophen Acetaminophen may decrease the excretion rate of Potassium sulfate which could result in a higher serum level. Acetazolamide The risk or severity of dehydration can be increased when Acetazolamide is combined with Potassium sulfate. Acetylsalicylic acid Potassium sulfate may increase the hyperkalemic activities of Acetylsalicylic acid. Aclidinium The therapeutic efficacy of Potassium sulfate can be decreased when used in combination with Aclidinium. Acrivastine Acrivastine may decrease the excretion rate of Potassium sulfate which could result in a higher serum level. Acyclovir Acyclovir may decrease the excretion rate of Potassium sulfate which could result in a higher serum level. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Active Moieties
Name Kind UNII CAS InChI Key Potassium cation ionic 295O53K152 24203-36-9 NPYPAHLBTDXSSS-UHFFFAOYSA-N Sulfate ion ionic 7IS9N8KPMG 14808-79-8 QAOWNCQODCNURD-UHFFFAOYSA-L - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image BLACKMORES EXECUTIVE B TABLET Potassium sulfate (75 mg) + Ascorbic acid (180 mg) + Biotin (50 µg) + Cyanocobalamin (10 µg) + Folic acid (200 mcg) + Magnesium phosphate (175 mg) + Nicotinamide (60 mg) + Pantothenic acid (20 mg) + Pyridoxine hydrochloride (10 mg) + Riboflavin (8.5 mg) + Thiamine mononitrate (7.5 mg) + Zinc sulfate (15 mg) Tablet Oral BLACKMORES (MALAYSIA) SDN. BHD. 2020-09-08 Not applicable Malaysia 
ColPrep Kit Potassium sulfate (3.13 g/22.7g) + Magnesium sulfate (1.6 g/22.7g) + Sodium sulfate decahydrate (17.5 g/22.7g) Powder, for solution Oral KVK-Tech, Inc. 2016-12-27 2019-01-24 US 
Flex Capsules Potassium sulfate (50 mg / cap) + Calcium ascorbate (35 mg / cap) + Magnesium sulfate (17 mg / cap) Capsule Oral Foodscience Laboratories, Division Of Foodscience Corporation 1998-07-02 2006-06-16 Canada 
Kanga Sport Vitamins B & C Plus Minerals Potassium sulfate (34 mg) + Ascorbic acid (1000 mg) + Biotin (180 mcg) + Cyanocobalamin (10 mcg) + Riboflavin 5'-phosphate sodium anhydrous (14 mg) + Magnesium sulfate (50 mg) + Nicotinamide (50 mg) + Calcium pantothenate (35 mg) + Pyridoxine hydrochloride (10 mg) + Thiamine (14 mg) Tablet, effervescent Oral Lacombe Drugs (1992) Ltd Not applicable Not applicable Canada Mega Min Capsules Potassium sulfate (22.4 mg / cap) + Calcium carbonate (125 mg / cap) + Cupric sulfate (1 mg / cap) + Ferrous fumarate (10 mg / cap) + Magnesium oxide (50 mg / cap) + Manganese sulfate (5 mg / cap) + Potassium Iodide (.1 mg / cap) + Sodium molybdate (.06 mg / cap) + Zinc sulfate (7.5 mg / cap) Capsule Oral Vita Health Products Inc 1988-12-31 1998-07-22 Canada Mega Vitaminerals Potassium sulfate (15 mg / cap) + Ascorbic acid (150 mg / cap) + Biotin (25 mcg / cap) + Calcium carbonate (125 mg / cap) + Cholecalciferol (200 unit / cap) + Choline bitartrate (8.33 mg / cap) + Chromium (12.5 mcg / cap) + Cupric sulfate (1 mg / cap) + Cyanocobalamin (25 mcg / cap) + Ferrous fumarate (8 mg / cap) + Folic acid (0.2 mg / cap) + Inositol (8.33 mg / cap) + Magnesium oxide (50 mg / cap) + Manganese sulfate (5 mg / cap) + Niacin (5 mg / cap) + Nicotinamide (25 mg / cap) + Calcium pantothenate (25 mg / cap) + Potassium Iodide (75 mcg / cap) + Pyridoxine hydrochloride (25 mg / cap) + Riboflavin (25 mg / cap) + Selenium (12.5 mcg / cap) + Sodium molybdate (12.5 mcg / cap) + Thiamine hydrochloride (25 mg / cap) + Vitamin A palmitate (10000 unit / cap) + Vitamin E (100 unit / cap) + Zinc sulfate (7.5 mg / cap) Capsule Oral Herbscience Custom Manufacturing Not applicable Not applicable Canada Multiple Vitamins and Minerals Capsules Potassium sulfate (15 mg / cap) + Ascorbic acid (150 mg / cap) + Biotin (25 mcg / cap) + Choline bitartrate (25 mg / cap) + Cupric sulfate (2 mg / cap) + Cyanocobalamin (25 mcg / cap) + Ferrous fumarate (18 mg / cap) + Folic acid (.4 mg / cap) + Inositol (25 mg / cap) + Manganese sulfate (15 mg / cap) + Nicotinamide (25 mg / cap) + Calcium pantothenate (25 mg / cap) + Potassium Iodide (.15 mg / cap) + Pyridoxine (25 mg / cap) + Riboflavin (25 mg / cap) + Thiamine mononitrate (25 mg / cap) + Vitamin A palmitate (5000 unit / cap) + Vitamin D (400 unit / cap) + Vitamin E (150 unit / cap) + Zinc sulfate (22 mg / cap) Capsule Oral Stanley Pharmaceuticals, A Division Of Vita Health Products Inc. 1986-12-31 1997-08-08 Canada NUTRAGESTA ® Potassium sulfate (18 mg) + Calcium carbonate (300 mg) + Cholecalciferol (0.44 mg) + Cobaltous sulfate heptahydrate (0.24 mg) + Cupric sulfate (2.517 mg) + Cyanocobalamin (1.15 mg) + Folic acid (1 mg) + Iron (95.4762 mg) + Magnesium sulfate (71 mg) + Manganese sulfate (3.1 mg) + Nicotinamide (8.189 mg) + Omega-3 fatty acids (555.56 mg) + Calcium pantothenate (17.5 mg) + Pyridoxine hydrochloride (1.05 mg) + Riboflavin (2.2 mg) + Sodium ascorbate (47.2879 mg) + Sodium fluoride (0.2 mg) + Sodium molybdate (0.1107 mg) + Thiamine (2.5 mg) + Vitamin A palmitate (3.3 mg) + Vitamin E (10.5 mg) + Zinc oxide (0.25 mg) Capsule, liquid filled Oral PROCAPS S.A. 2017-08-23 Not applicable Colombia 
Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Potassium sulfate (3.13 g/1mL) + Magnesium sulfate (1.6 g/1mL) + Sodium sulfate decahydrate (17.5 g/1mL) Solution, concentrate Oral Affordable Pharmaceuticals, LLC 2010-08-05 Not applicable US Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Potassium sulfate (2.35 g/133.1mL) + Magnesium sulfate (1.2 g/133.1mL) + Sodium sulfate decahydrate (13.13 g/133.1mL) Solution, concentrate Oral Affordable Pharmaceuticals, LLC 2010-08-05 Not applicable US
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as alkali metal sulfates. These are inorganic compounds in which the largest oxoanion is sulfate, and in which the heaviest atom not in an oxoanion is an alkali metal.
- Kingdom
- Inorganic compounds
- Super Class
- Mixed metal/non-metal compounds
- Class
- Alkali metal oxoanionic compounds
- Sub Class
- Alkali metal sulfates
- Direct Parent
- Alkali metal sulfates
- Alternative Parents
- Inorganic salts / Inorganic oxides
- Substituents
- Alkali metal sulfate / Inorganic oxide / Inorganic salt
- Molecular Framework
- Not Available
- External Descriptors
- potassium salt (CHEBI:32036)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 1K573LC5TV
- CAS number
- 7778-80-5
- InChI Key
- OTYBMLCTZGSZBG-UHFFFAOYSA-L
- InChI
- InChI=1S/2K.H2O4S/c;;1-5(2,3)4/h;;(H2,1,2,3,4)/q2*+1;/p-2
- IUPAC Name
- dipotassium sulfate
- SMILES
- [K+].[K+].[O-]S([O-])(=O)=O
References
- General References
- Not Available
- External Links
- KEGG Compound
- C13192
- ChemSpider
- 22915
- ChEBI
- 32036
- ChEMBL
- CHEMBL2021424
- Wikipedia
- Potassium_sulfate
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Bowel preparation therapy / Colonoscopy / Endoscopy 1 4 Unknown Status Diagnostic Colonoscopy 1 3 Completed Other Digestive System Diseases 1 3 Completed Treatment Healthy Subjects (HS) 1 Not Available Completed Not Available Bowel preparation therapy 1 Not Available Unknown Status Diagnostic Inpatient Colonoscopy / Oral Sulfate Solution / Polyethelene Glycol 1 Not Available Withdrawn Screening Colorectal Cancer 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral Powder, for solution Oral Solution Oral 1.6 g Tablet, effervescent Oral Capsule, liquid filled Oral 1 mg Capsule Oral Solution Oral Kit Oral Solution, concentrate Oral Capsule, liquid filled Oral - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US6946149 No 2005-09-20 2023-03-07 US
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP -0.84 Chemaxon pKa (Strongest Acidic) -3 Chemaxon Physiological Charge -2 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 80.26 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 11.53 m3·mol-1 Chemaxon Polarizability 5.81 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Steroid hormone binding
- Specific Function
- This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates th...
- Gene Name
- ATP1A1
- Uniprot ID
- P05023
- Uniprot Name
- Sodium/potassium-transporting ATPase subunit alpha-1
- Molecular Weight
- 112895.01 Da
References
- Silva E, Gomes P, Soares-da-Silva P: Overexpression of Na(+)/K (+)-ATPase parallels the increase in sodium transport and potassium recycling in an in vitro model of proximal tubule cellular ageing. J Membr Biol. 2006;212(3):163-75. Epub 2007 Feb 28. [Article]
- Li C, Geering K, Horisberger JD: The third sodium binding site of Na,K-ATPase is functionally linked to acidic pH-activated inward current. J Membr Biol. 2006;213(1):1-9. Epub 2007 Mar 8. [Article]
- Stanely Mainzen Prince P, Karthick M: Preventive effect of rutin on lipids, lipoproteins, and ATPases in normal and isoproterenol-induced myocardial infarction in rats. J Biochem Mol Toxicol. 2007;21(1):1-6. [Article]
- Simon WA, Herrmann M, Klein T, Shin JM, Huber R, Senn-Bilfinger J, Postius S: Soraprazan: setting new standards in inhibition of gastric acid secretion. J Pharmacol Exp Ther. 2007 Jun;321(3):866-74. Epub 2007 Mar 16. [Article]
- Iannello S, Milazzo P, Belfiore F: Animal and human tissue Na,K-ATPase in normal and insulin-resistant states: regulation, behaviour and interpretative hypothesis on NEFA effects. Obes Rev. 2007 May;8(3):231-51. [Article]
Drug created at July 11, 2018 16:29 / Updated at February 21, 2021 18:54